elotuzumab
Multiple myeloma treatment from BMS and AbbVie scores EU approval
May 12, 2016Research and Development, Sales and Marketing AbbVie, BMS, EMA, EU, Empliciti, approval, bristl-myers squibb, elotuzumab, multiple myeloma
Bristol-Myers Squibb (NYSE: BMY) and AbbVie (NYSE: ABBV) have announced that the European Commission has approved Empliciti (elotuzumab) for the …
FDA approves BMS and AbbVie’s Empliciti for multiple myeloma
December 1, 2015Manufacturing and Production, Sales and Marketing AbbVie, BMS, Bristol-Myers Squibb, Empliciti, FDA, elotuzumab, multiple myeloma
The US healthcare regulator has approved Empliciti – a multiple myeloma treatment co-developed by Bristol-Myers Squibb and AbbVie. The FDA …
Priority review for Novartis myeloma drug
November 26, 2014Sales and Marketing FDA, Farydak, Novartis, daratumumab, elotuzumab, myeloma, odac
Novartis’ multiple myeloma treatment Farydak has been given an extended review by the FDA after its future seemed in jeopardy …
BMS and AbbVie get FDA lift
May 21, 2014Research and Development, Sales and Marketing AbbVie, BMS, FDA, elotuzumab, multiple, myeloma
Bristol-Myers Squibb and AbbVie are celebrating after receiving breakthrough designation status from the US regulator for their investigational medicine elotuzumab …
